ERBB2 and non-small cell lung carcinoma: Another notable example of the adverse effects of current ADCs is the occurrence of T-DXd-induced ILD in both HER2-expressing metastatic colorectal cancer [11] and non-small-cell lung cancer (NSCLC) [6].